BioInsights - Driving development and commercialization of iPSCderived allogeneic T cell therapies

Driving development and commercialization of iPSCderived allogeneic T cell therapies

Cell & Gene Therapy Insights 2021; 7(12), 1833–1837

10.18609/cgti.2021.279

Published: 31 January 2022
Interview
David Dow

David McCall, Editor, Cell and Gene Therapy Insights, speaks to David Dow, Senior Director, Allogeneic Research, Adaptimmune

David Dow is Senior Director, Allogeneic Research at Adaptimmune where he is leading the Allogeneic Research group. He joined Adaptimmune from GSK, where he was a program leader in the pre-clinical development of cell therapies for cancer. Prior to this, he was a member of the GSK/TIGET team that developed Strimvelis, achieving EMA authorisation in 2016, for which the team received two international Prix Galien awards. David has a PhD in Genomic Medicine from the University of East Anglia and is an alumnus of the Said Business School and Oriel college, Oxford, where he studied Strategy and Innovation. He has co-authored on publications in several leading journals including Science, Nature and The Lancet and is a guest lecturer at Cambridge University.